In late May 2026, CNBC’s Jim Cramer spotlighted SELLAS Life Sciences Group on “Mad Money,” praising its potential as a speculative investment amid developments in its Phase 3 REGAL trial for its AML treatment, GPS. Attention is also growing around another candidate, SLS009, with expected topline data seen as a crucial catalyst. However, despite recent interest, the company continues to face revenue challenges and risks related to ongoing losses, raising concerns about whether its stock is overvalued. Watch for the upcoming trial data, as the outcomes will be pivotal for the company’s future.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/why-sellas-life-sciences-group-sls-is-up-197-after-cramer-en
